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Age-related waning of immune 
responses to BCG in healthy 
children supports the need for a 
booster dose of BCG in TB endemic 
countries
Elizabeth Whittaker1,2, Mark P. Nicol2, Heather J. Zar3,4, Nontobeko G. Tena-Coki4 & 
Beate Kampmann1,5
In the absence of a more effective vaccine against TB and in the interest of developing one, it is essential 
to understand immune responses associated with BCG protection. We comprehensively characterized 
T cell populations in BCG-vaccinated children over time. Blood from 78 healthy, BCG-vaccinated 
children representing four age groups (<1 yr, ≥1 yr <2 yr, ≥2 yr <5 yr, ≥5 yr), was stimulated in 
vitro for 24 hours and 6 days with live BCG to induce effector and central memory responses. Antigen-
specific CD4, CD8, γδ and regulatory T cell populations were phenotyped and intracellular and secreted 
cytokines measured by flow cytometry and multiplex ELISA respectively. Our results demonstrated 
that populations of naïve T cells predominated in infants, compared to older children. However, BCG-
specific effector CD4 T cell responses were equivalent and antigen-specific CD4 T cell proliferative 
capacity was increased in infants compared to older children. Increases in innate immune responses 
including γδ T cell responses and secreted pro-inflammatory cytokines were noted with increasing age. 
In conclusion, we identified that the capacity to expand and differentiate effector T cells in response 
to BCG stimulation wanes with increasing age, which may indicate waning central memory immunity. 
Booster vaccination could be considered to maintain the antigen-specific central memory pool and 
possibly enhance the duration of protection.
A protective vaccine with higher efficacy than BCG remains an essential tool to combat the ongoing tuberculosis 
(TB) epidemic1. In the meantime, BCG remains a widely-used vaccine with varying protection against pulmo-
nary TB (0–80%), but proven efficacy against disseminated disease in children under 5 years of age2. Despite its 
widespread use for nearly a century, the mechanisms of immune protection imparted by BCG remain poorly 
understood. Understanding how BCG confers protection - or fails to do so- is central to the development of new 
vaccines that aim to either boost its efficacy or replace it altogether3, and correlates of immune protection against 
TB still remain elusive.
In addition to epidemiological risk factors such as close contact between infants and their TB-transmitting 
caregivers, increasing immune maturation is likely to underlie the observation that the risk of severe manifes-
tations of TB decrease with increasing age, and is comparable with adults by the age of 5 years4. Correlates of 
protection are therefore likely to be distinct between adults and infants.
1Academic Department of Paediatrics, St Marys Campus, Imperial College London, 2nd Floor Wright-Fleming 
Building, Norfolk Place, London, W2 1PG, UK. 2Division of Medical Microbiology, Department of Pathology And 
Institute of Infectious Disease and Molecular Medicine UCT Faculty of Health Sciences, Observatory, 7925, South 
Africa. 3MRC Unit of Child & Adolescent Health, University of Cape Town, Rondebosch, Cape Town, 7701, South 
Africa. 4Department of Paediatrics & Child Health, Red Cross War Memorial Children’s Hospital, Klipfontein 
Road, Rondebosch, Cape Town, 7701, South Africa. 5Vaccines & Immunity Theme MRC Unit The Gambia Fajara, 
Serrekunda, West Africa, The Gambia. Correspondence and requests for materials should be addressed to E.W. 
(email: e.whittaker@imperial.ac.uk)
Received: 10 April 2018
Accepted: 28 September 2018
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2Scientific REpoRTs |  (2018) 8:15309  | DOI:10.1038/s41598-018-33499-4
The role of IFNγ as an immune correlate of protection induced by BCG vaccination has been questioned, par-
ticularly through a large cohort study of BCG vaccinated South African infants5. Murine data support the hypoth-
esis that the balance between mycobacterial antigen-specific IL17 and IFNγ producing T cells is of importance in 
mediating BCG-induced protection6 but gaps in knowledge remain in the context of such responses in children. 
Neonates are recognized to have diminished IFNγ production compared to adults, which may contribute to their 
susceptibility to disseminated disease, this may be associated with raised levels of Th17-associated cytokines. 
Furthermore, infants have increased numbers of circulating regulatory T cells which may contribute to lower 
levels of IFNγ and susceptibility to TB disease7,8.
Immune cell populations and effector molecules induced by BCG vaccination have been described in 
cross-sectional studies from a variety of countries, including in children of different ages5,9–11. These include 
CD8+ T cells, γδ T cells, Th17 cells, polyfunctional T cells and regulatory T cells, but to date no studies of the 
longevity of the responses have been published.
We therefore characterized age-related antigen-specific and non-specific effector and central memory 
responses to BCG, including Th1, Th17 and regulatory T cell populations and their associated cytokines in chil-
dren to examine why BCG vaccine efficacy wanes with age.
Methods
Study setting. The study was conducted at the Red Cross War Memorial Children’s Hospital (RCH) in 
Cape Town, South Africa. Ethical approval was obtained from the Faculty of Health Sciences Research Ethics 
Committee at the University of Cape Town (HREC: 062/2011). Following written informed consent from the 
legal guardian, blood samples were taken. The study was carried out in accordance with the local regulations.
Eligibility. Healthy children who presented to RCH for elective surgical interventions were recruited for this 
study. A medical and TB contact history was documented prior to recruitment. Only children with a written 
record of BCG vaccination (BCG Denmark strain) at birth were included. Exclusion criteria were a history of 
significant household contact with TB; previous treatment for TB; recurrent infections or hospital admissions; 
persistent cough for longer than 2 weeks; intercurrent febrile illness; failure to thrive or known immunodeficiency 
including HIV infection. If HIV status was unknown, an HIV test was performed following counselling. All chil-
dren were screened for Mycobacterium tuberculosis sensitisation using Quantiferon TB Gold In Tube (Cellestis, 
Carnegie, Australia). Only healthy children without evidence of M. tuberculosis sensitization were included.
Blood collection, stimulation and cryopreservation. 0.5 ml of heparinised blood was incubated within 
4 hours of collection with BCG (SSI strain, 5 × 105 colony forming units (cfu)/ml), as previously described12. 
Medium alone served as negative control; staphylococcal enterotoxin B (SEB 10 µg/ml final concentration; Sigma, 
UK) was used as a positive control. Brefeldin-A was added for the last 5 hours of the 20-hour incubation. Cells 
were then harvested, fixed, and cryopreserved.
A further 0.25 ml aliquot of whole blood (diluted 1:10 in RPMI 1640) was incubated with BCG (SSI, 
2.5 × 106 cfu/ml) for 6 days for a Ki67 lymphoproliferation assay as previously described13 or with medium 
alone or SEB (5 µg/ml final concentration) as negative and positive controls respectively. To assess intracellular 
cytokine production, 10 ng/mL phorbol 12-myristate 13-acetate (PMA, Sigma-Aldrich), 1.5 µg/mL ionomycin 
(Sigma-Aldrich) and 1.5 µg/mL Brefeldin A (Sigma-Aldrich) were added during the last 5 h of culture. Cells were 
then harvested, stained with a viability dye, fixed and cryopreserved.
Prior to the addition of PMA/Ionomycin/Brefeldin, 500 μl of supernatant was removed and stored at −80 °C 
for subsequent analysis by multiplex ELISA (Bio-plex ProTM Human Th17 Cytokine Panel) to determine levels of 
secreted chemokines and cytokines.
Cell staining and flow cytometric analysis. Cryopreserved cells were thawed, washed, and per-
meabilized with Perm/wash solution (BD Biosciences). Cells were then incubated at 4 °C for 1 hour with 
fluorescence-conjugated antibodies directed against surface antigens and intracellular cytokines. For detection of 
the transcription factor FOXP3, a nuclear permeabilisation buffer (eBioscience) was used in place of the Perm/
Wash solution as per manufacturer’s protocol. The following fluorescence-conjugated antibodies were used: 
anti-CD3 PacBlue, anti-GDTCR PE, anti-CD27 PECy7, anti-CD25 APC, anti-IFNγ Alexafluor 700, anti-IL17A 
Alexafluor 647, anti-Ki67FITC (all BD biosciences, San Jose, CA); anti-CD45RA QDot655, anti-CD8 QDot605, 
anti-CD4 QDot605 (all Invitrogen, Eugene, Or); anti-CD39 FITC, anti-IL22 PerCP-Efluor710, anti-FOXP3 PE 
(all eBioscience, SanDiego, CA).
The entire sample was acquired on a BD LSR Fortessa Flow Cytometer (model 649225B7, power 690 W, man-
ufactured Sept 2010) configured with 4 lasers and 22 detectors using FACSDiva software (BD Bioscience, San 
Jose, CA, USA). Compensation for overlap of fluorescence detection was performed using compensation beads. 
Multiparameter panel development included evaluation of appropriate staining controls of antibody and fluoro-
chrome interactions and of spectral overlap using control blood samples.
Secreted cytokine measurement. Concentrations of IL1β, IL4, IL6, IL10, IL17, IL22, IL23, IFNγ, 
TNFα were measured in supernatants from whole blood stimulated for 6 days by Milliplex MAP Multiplex 
Immunoassay (based on Luminex MAP technology; Millipore) on a Bio-Rad Luminex 100 Bio-Plex Liquid Array 
Multiplexing System Fluorescent Reader, according to the manufacturer’s instructions. The following concentra-
tions of the standards diluted in 200 μl assay buffer were used: 10000, 2000, 400, 80, 16, and 3.2 pg/ml.
Data analysis. Multi-parameter flow cytometry data was analysed using FlowJo v 9.4.11 (TreeStar, Ashland, 
OR). Combinations of cytokine-producing cells were determined by Boolean Gating in FlowJo.
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SPSS and GraphPad Prism were used for statistical analysis. Negative control (background) values for cytokine 
expression were subtracted from BCG-induced responses. An empiric cut-off value of 0.01% was interpreted 
as a positive response in line with previous publications14. Differences between groups were calculated using 
either Mann-Whitney or Kruskal-Wallis analysis of variance. For correlations, a Spearman coefficient for 
non-parametric data was calculated. All tests were two-tailed and a value of p < 0.05 was considered significant.
Results
78 children were recruited to the study, stratified in 4 age groups of comparable sizes and reflective of the 
reported age-dependent susceptibility to TB disease (group 1: <1 yr n = 19, group 2: ≥1 yr < 2 yr n = 18, group 3: 
≥2 yr < 5 yr n = 22, group 4: ≥5 yr n = 19). Malnutrition, as measured by z-score was uncommon in this cohort. 
All children were fully vaccinated according to the South African schedule.
Age-dependent SEB and BCG-induced T cell responses. To examine the age-dependent T cell effector 
responses to BCG or SEB stimulation in vitro, we measured the magnitude of responses by flow cytometry and 
quantified CD4+, CD8+ and γδ + T cells expressing IFNγ, IL17 and IL22. Following stimulation with BCG in 
vitro, BCG specific T cell responses were observed in all children, in particular all children demonstrated measur-
able IFNγ CD4+ T cell responses with no significant differences between the age groups (Fig. 1B). Interestingly, 
in response to the positive control antigen SEB, there was a significantly lower proportion of IFNγ producing 
CD4+ T cells in infants compared to those in all older age groups (Fig. 1B). The same pattern of response to SEB 
was observed in γδ (Fig. 1D) and CD8+ T cell responses (Data not shown). BCG specific IFNγ producing γδ T 
cells were significantly higher in children over five years compared to those under a year of age (Fig. 1D) (>5 yrs 
median 0.7% [IQR 0.05–1.8] vs <1 yr median 0.25 [IQR 0.04–0.46]; p = 0.04).
IL22 expressing BCG specific CD4+ T cells were produced in all ages, and their frequency were noted to be 
significantly higher in children over two years of age compared to infants (Fig. 1C). In contrast, BCG specific 
IL22 producing γδ T cell frequencies were higher in infants under 1 year of age compared to older infants (<1 yr 
median 0.245 [IQR 0.07–0.78] vs >5 yr median 0.05 [IQR 0.015–0.12]; p = 0.02) (data not shown). BCG specific 
IL17 production was low in all T cell types with a high number of non-responders (data not shown).
BCG-induced secreted cytokine levels demonstrate decreased pro-inflammatory responses 
in infants. To explore functional properties of the T cells involved in Th1/Th17 pathways, we measured 
pro-inflammatory and effector cytokines secreted following BCG stimulation of whole blood in vitro for 6 days. 
The levels of IL1β, IL6, IL23 and TNFα were lower in children <1 yr of age compared to older children (Fig. 2), 
but there were no differences in levels of IFNγ, IL17 or IL22. There was a trend to increasing levels of IL4 with 
age, only reaching significance between children ≥1 < 2 yrs and those ≥2 < 5 yrs of age (Fig. 2). There were no 
significant differences in the other cytokines measured as part of this panel (IL10, IL21, IL31, IL33 or sCD40L; 
data not shown)
Influence of age on proliferative capacity of T cells following BCG stimulation for 6 days. In 
order to determine potential differences in antigen-specific proliferative capacity and between the four age 
groups, a six day lymphoproliferation assay using Ki67 was carried out. The frequency of BCG stimulated pro-
liferating CD4+ T cells decreased with increasing age, with significantly fewer cells in children >5years of age 
compared to infants and children under 2 years of age (Fig. 3A). To explore potential functional differences, key 
intracellular cytokines produced by BCG stimulated Ki67+ CD4+ T cells were also measured. Antigen-specific 
intracellular IFNγ decreased significantly with increasing age (Fig. 3A). The same pattern was noted in γδ and 
CD8+ T cells (data not shown). The median frequencies of IL17 and IL22 production by Ki67+ T cells of all 
phenotypes were low with a high number of non-responders, and there were no significant differences between 
the age groups (data not shown).
To determine whether these responses represented antigen-specific or generic responses, Ki67 proliferative 
responses, including cytokine expression, were also measured following stimulation with SEB. There was a signifi-
cant increase in proliferative capacity of CD4+ T cells in response to SEB with increasing age, in contrast with the 
BCG specific responses which decreased with increasing age. There were no significant differences in intracellular 
cytokines produced by proliferating cells with increasing age (Fig. 3B).
No significant differences were seen in the proliferative response or cytokine production of γδ or CD8+ T cells 
in the four age groups following 6-day stimulation with SEB (Data not shown).
Regulatory T cells in immune response to mycobacteria. To determine the influence of age 
on circulating regulatory T cells in unstimulated and BCG stimulated whole blood, the frequency of 
CD4+CD25+CD39+FOXP3 T cells was measured in all four age groups. The frequency of regulatory T cells 
was found to increase significantly with increasing age (Fig. 4). To determine whether these regulatory T cells 
had a functional correlate, we measured the levels of IL10 in plasma collected from whole blood stimulated with 
BCG for 6 days and correlated regulatory T cells as well as Th1/Th17 cell phenotypes. No significant differences 
were observed. Furthermore, there were no significant correlations between regulatory T cells and frequency of 
Th1 or Th17 cytokine expression in CD4+, CD8+ or γδ T cells between any of the age groups. (Data not shown).
Memory phenotype of BCG specific CD4 T cells. Given the age-related differences in the proliferative 
capacity and cytokine production of T cells, in particular CD4 T cells, we next investigated whether these were 
associated with shifts in the CD4 T cell memory phenotype. The T cell memory phenotype in unstimulated 
whole blood was defined by expression of CD27 and CD45RA on the cell surface. Conventionally, dual positive 
cells (CD27+CD45RA+) are considered naïve; expression of CD27 alone (CD27+CD45RA−) is described as 
a central memory population; the absence of CD27 allows cells to migrate to the site of infection, those that 
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express neither marker (CD27−CD45RA−) are described as effector memory T cells, while those that re-express 
CD45RA (CD27−CD45RA+) are terminally differentiated memory cells. A naïve CD4 T cell phenotype, 
CD27+CD45RA+, predominated in all age groups and decreased from 80% in infants to 49% in children older 
than 5 years (p < 0.0001) (Fig. 5A).
Figure 1. Children of all ages have measurable BCG specific CD4+ IFNγ responses, but non-specific 
responses increase with increasing age. (A) Flow cytometric plots from a representative individual infant 
showing intracellular IFNγ, IL17 or IL22 cytokine secretion by BCG stimulated CD4+ T cells are shown. (B) 
Frequencies of IFNγ producing CD4+ T cells, (C) IL22 producing CD4+ T cells or (D) IFNγ producing γδ T 
cells, as detected by an intracellular cytokine assay following stimulation of whole blood with SEB or BCG for 
20 hours, are shown. Horizontal bars represent median values. The dotted line represents a cut-off of 0.01% for a 
significant response. The Mann-Whitney test was used to calculate p values.
www.nature.com/scientificreports/
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As expected, IFNγ was produced by antigen-specific CD4+ T cells. Although the patterns differed and there 
was a trend to fewer effector T cells with increasing age, there were no significant age-related differences between 
the four memory phenotypes (Fig. 5B).
The memory phenotype of proliferating CD4+ T cells was determined by measuring expression of CD27 and 
CD45RA surface markers. In infants, the majority of the cytokine producing Ki67 proliferating CD4+ T cells fol-
lowing BCG stimulation in vitro were expressing an effector memory phenotype (CD27−CD45RA−). In contrast, 
Figure 2. Secretion of IL1β, IL6 and TNFα was significantly lower in infants than older children. Cytokines 
were measured in supernatants from diluted whole blood cultures, stimulated with BCG for 6 days using a 
multiplex assay. Horizontal bars represent median values. Data shown on a log scale. A Mann Whitney test was 
used to calculate p values.
www.nature.com/scientificreports/
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in older children, there was greater heterogeneity with increased representation of the naïve (CD27+ CD45RA+) 
and central memory (CD27+CD45RA−) phenotypes (Fig. 5C) (CD27−CD45RA− expressing Ki67+CD4 T 
cells – infants <1 yr median 96.8% (IQR 90.6–98.4) vs children >5 yr median 44.7% (IQR 30.3–68.2); p < 0.0001). 
The memory phenotypes of all CD4+ and γδ T cells producing cytokines (IFNγ, IL17 and IL22) were similar 
(data not shown).
Discussion
This study sought to expand our understanding of phenotypic and functional characteristics of T cell populations 
in relation to BCG vaccination beyond infancy and including CD4, CD8, γδ and regulatory T cells and relevant 
cytokines in children. We found significant changes in antigen-specific and non-specific T cell responses related 
to age and time since receiving BCG vaccination with a contrasting pattern induced by antigen-specific and 
non-specific stimulation in vitro. Whilst waning efficacy of BCG is well described in the literature15,16, the under-
lying mechanisms have remained unclear. Our data, in South African children, support the notion that waning 
immunity to BCG over time could be due to waning of BCG-specific proliferation and expansion of effector CD4 
T cells with age, associated with an increase in regulatory T cells.
Our data confirmed that healthy, BCG vaccinated children of all ages have measurable CD4+ T cell effector 
responses to BCG17. Conventional T cell effector responses, as defined by IFNγ producing CD4+ T cells, are an 
integral part of the immune response to mycobacteria. However recent studies demonstrate that IFNγ producing 
CD4+ T cells induced by either BCG or the TB vaccine candidate MVA85A, do not correlate with protective 
immunity5,18,19.
Based on results from animal studies, we anticipated that infants would have more robust Th17-associated 
responses than older children, measured as IL17 and IL22 production in response to BCG stimulation in our 
study. However, our data show that although IL17 was produced by both CD4+ and γδ T cells in response to BCG 
stimulation in vitro in some children, there were no clear patterns, with IL 17 levels either low or non-measurable 
in each age group. In contrast, the production of IL22 by γδ T cells was higher in younger children and decreased 
in older children in parallel with increasing IFNγ levels.
Figure 3. The frequencies of Ki67+ CD4 and IFNγ expressing Ki67 CD4+ T cells following stimulation 
with BCG (A) or SEB (B) for 6 days are shown. Ki67 proliferation and expression of IFNγ in response to BCG 
stimulation in vitro wanes with increasing age, however non-specific proliferation due to SEB increases with 
increasing age. Horizontal bars represent median values.
www.nature.com/scientificreports/
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Despite the robust antigen specific CD4 T cell responses, other measures of immunity- such as lower 
non-specific SEB induced T cell responses, lower levels of BCG-induced IL1β, IL6 and TNFα and BCG-induced 
γδ T cell responses- were distinctly different in infants compared to older children. Previous studies of healthy 
BCG vaccinated infants have measured production of TNFα and IL6 as measures of non-adaptive responses 
following stimulation with TLR agonists or PPD in whole blood in vitro, but did not include children older than 
12 months of age20,21. Shey et al. demonstrated increasing levels of TNFα, IL6 and IL12p40 by BCG stimulated 
monocytes from birth to 9 months, but did not explore these responses in older children22. In contrast, a further 
study of TLR responses in neonates and children up to 2 yrs of age in comparison to adults showed that IL6 and 
IL23 levels fell from birth to 2 yrs, by which time they were comparable to adult levels23. These differences may be 
explained by a shorter stimulation period (6 or 18 hours vs 6 days) and the use of specific TLR agonists rather than 
live BCG, which is likely to elicit different patterns of responses.
Limitations in the adaptive immune responses of infants are thought to reflect the naive state of most of their 
circulating T cells. Although the infants in this cohort had increased numbers of naïve T cells ex-vivo, these were 
able to differentiate into effector and central memory phenotypes in response to BCG stimulation. BCG specific 
CD4+ T cells from children of all ages in our cohort displayed phenotypic characteristics of both central memory 
and effector memory T cells, as previously shown by Soares et al. in children of up to 1 year of age15, possibly due 
to ongoing antigenic stimulation due to persistence of BCG, non-tuberculous mycobacteria(NTM) or indeed 
Mycobacterium tuberculosis in this highly endemic setting. However, when we examined the memory pheno-
type of BCG specific proliferating T cells, significant differences in the pattern of differentiation of these T cells 
between infants and older children were found. Following 6 days incubation of whole blood with BCG, almost the 
entire BCG specific T cell population in infants expressed an effector memory phenotype, whereas older children 
expressed a mixture of all memory phenotypes, with a greater central memory population.
Figure 4. Regulatory T cells (A) Representative plots from a healthy control child are shown. From left to 
right, CD3 vs Time is shown to detect differences in flow. Cell doublets were excluded with forward scatter area 
versus forward scatter height parameters. Plotting FSC-A vs SSC-A allows identification of the lymphocyte 
population based on size and granularity. CD4+CD3+T cells were identified, followed by CD4+CD25+T cells. 
Using FMO gates, FOXP3 and CD39 gates were placed to identify the CD3+CD4+CD25+CD39+FOXP3+ 
population. Age-related frequency of regulatory T cells in (B) unstimulated whole blood and (C) whole blood 
incubated with BCG for 20 hours. Horizontal bars represent median values.
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The current literature has few and conflicting data regarding the relationship between regulatory T cells and 
age. We found that the frequency of circulating regulatory T cells increases with increasing age, both in unstim-
ulated and BCG stimulated blood. Two South American studies have shown an inverse correlation between 
CD4+CD25+Foxp3+T cells and patient age in children from 1 yr to 19 yrs of age24,25. However, a Japanese group 
found that numbers stabilized and did not change after the first few days of life26. Recent work has shown signifi-
cant differences in TLR innate immune responses in infants across four continents27, and it is likely that regional 
differences in regulatory T cell profiles also exist. Of note, IL10, a cytokine often produced by regulatory T cells, 
was noted to be decreased in the South African cohort compared to others in that study. One hypothesis to 
explain lower levels of regulatory T cells in the younger children in this cohort may be that BCG vaccination 
in the newborn period induces a strong Th1 response which is known to suppress regulatory T cell numbers. 
Regulatory T cells have previously been shown to be increased in adults and children with tuberculosis dis-
ease8,28–30 and are present in higher numbers in extra-pulmonary compared to pulmonary disease8,31,32, hence 
BCG induced suppression of regulatory T cells may indicate a mechanism of protection. Further studies includ-
ing BCG unvaccinated cohorts would need to be conducted to conclude on this hypothesis. This study did not 
explore a direct functional effect of regulatory T cells on BCG induced CD4+ or γδ T cell responses, but it would 
be of interest to explore this in vitro or in an animal model, in particular focusing on the potential effect of regu-
latory T cell attenuation in the context of a booster dose of BCG vaccine33.
BCG vaccine appears to protect infants and young children only from disseminated disease in high endemic 
settings, and the short lived duration of protection has been attributed to either its failure to induce long lived 
memory cells or a gradual loss of BCG specific T cells34. Our data are in keeping with a gradual loss of the capac-
ity to expand and differentiate BCG-specific effector T cells following re-stimulation with mycobacteria with 
increasing age. Boosting the BCG vaccine response, either through BCG revaccination or with a novel vaccine, 
may have a beneficial role in high endemic settings. There has however been controversy surrounding the role of 
BCG revaccination. Initial data from a large adolescent revaccination study did not report a protective benefit35. 
However data from longer term follow up show evidence of protection in some subpopulations36,37, in particular 
children under the age of 11, living in regions with lower NTM exposure. More recently, Dye et al. estimated the 
potential benefit of revaccinating adolescents with BCG and concluded that it could be both cost effective and 
efficacious in some settings38. Recently, in a prevention-of-infection Phase 2 trial of the novel vaccine candidate 
H4:IC31 conducted in South African adolescents, revaccination with BCG significantly reduced TB infections39. 
Revaccination is not associated with an increased risk of adverse events40, and there may be beneficial heterolo-
gous effects41.
Our study has some limitations: our data are cross-sectional rather than longitudinal and it would have been 
interesting to monitor changes in individuals over time. However, the associated frequent blood tests and the 
required time frame present an obstacle to such longitudinal work. In our cohort, BCG is likely to have ‘primed’ 
the immune response, resulting in robust antigen specific T cell responses, but we could not include an unvacci-
nated cohort, as this would be unethical in a highly endemic setting such as in South Africa.
Figure 5. (A) The frequency of CD4+ T cell memory phenotypes as described by expression of CD27 and 
CD45RA in the four age groups is shown. (B) Memory phenotype of BCG specific IFNγ expressing CD4+ T 
cells in children of different age groups after 20 hours stimulation with BCG and (C) after 6 days stimulation 
with BCG.
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In summary, our data confirm that infants mount comprehensive T cell responses but that recall responses to 
BCG wane with age. There are distinct differences in the innate immune responses and circulating regulatory T 
cell levels in infants compared to older children that may contribute to susceptibility to mycobacteria and warrant 
further investigation. As central memory responses to BCG are affected by age, revaccinating children before 
adolescence with its associated peak in TB disease might be beneficial in high endemic areas.
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